Distribution of ABCB1 Genetic Variants and their Association with Moxifloxacin Pharmacokinetics in Hospitalized Patients with Acute Exacerbation of COPD
References
- Ulldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest. 2011;139(5):1210–1220.
- Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473–3478.
- Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75(1):13–33.
- Franke RM, Gardner ER, Sparreboom A. Pharmacogenetics of drug transporters. Curr Pharm Des. 2010;16(2):220–230.
- Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014;10(10):1337–1354.
- Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002;12(6):437–450.
- Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525–528.
- Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71(4):297–303. doi:10.1067/mcp.2002.122055.
- Naumovska Z, Nestorovska AK, Sterjev Z, Filipce A, Dimovski A, Suturkova L. Genotype variability and haplotype profile of ABCB1 (MDR1) gene polymorphisms in Macedonian population. Prilozi. 2014;35(3):121–133.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025 Report.
- Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock. Crit Care. 2009;13(3):214.
- Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill. Lancet Infect Dis. 2014;14(6):498–509.
- Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother. 1999;43(Suppl B):83–90. doi:10.1093/jac/43.suppl_2.83.
- Wise R, Andrews JM, Marshall G, Hartman G. Pharmacokinetics and inflammatory fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother. 1999;43(6):1508–1510.
- Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J. 1999;14(1):221–229.
- Zhu L, Wang N, Wang C, Yan S, Zhou J, Liu M, et al. Prediction of pharmacokinetics and penetration of moxifloxacin in various tissues in intra-abdominal infected human using a physiologically based pharmacokinetic model. Biopharm Drug Dispos. 2015;36(4):211–223. doi:10.1002/bdd.1932.
- Annisa N, Afifah NN, Santoso P, Yunivita V, te Brake LHM, Aarnoutse RE, et al. Pharmacogenetics and Pharmacokinetics of Moxifloxacin in MDR-TB Patients in Indonesia: Analysis for ABCB1 and SLCO1B1. Antibiotics (Basel). 2025;14(2):204.
- Czyrski A, Sokół A, Szałek E. HPLC method for determination of moxifloxacin in plasma and its application in pharmacokinetic analysis. J Liq Chromatogr Relat Technol. 2017;40(1):8–12.
- Stocco G, Lucafò M, Decorti G. Pharmacogenomics of antibiotics. Int J Mol Sci. 2020;21(17):5975.
- Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient: concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11. doi:10.1016/j.addr.2014.07.006.
DOI: https://doi.org/10.2478/bjmg-2026-0011 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160
Language: English
Page range: 17 - 22
Published on: Oct 14, 2026
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 O Krstic Nakovska, M Staninova Stojovska, E Mihajloska, Godzo H, A Debreshlioska, A Tatabitovska, D Karkinski, Lj Suturkova, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution 4.0 License.